Across its top 9 institutional holders, CLRO's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 12/100, avg. turnover score 40/100).

Quarterly Activity

Recent Activity

+$352.3K

Total Buy Value

$158.8K

Total Sell Value

New buy1

Trim1

Add2

Sold out3

Net Buyers

Net Sellers

Smart Money Convergence

CLRO does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/CLRO

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-06

2026-07-06

ClearOne (NASDAQ: CLRO) entered into a merger agreement on July 1, 2026 to acquire Cortigent through a subsidiary, making Cortigent a wholly-owned subsidiary. Vivani Medical, the seller, will receive 12.5 million shares of ClearOne common stock. ClearOne also plans a concurrent public offering of $10–$15 million subject to stockholder approval. Post-closing, the board will have five members, with Jonathan Adams as President & CEO, Ed Sedo as CFO, and Rachel Evans as Corporate Secretary.

View Full Filing (SEC EDGAR)

2026-07-01

ClearOne Inc. signed a loan agreement with First Finance Ltd. for up to $1 million. The loan will be advanced in tranches, with an initial $500,000 and possible additional $250,000 tranches. It carries an 11% annual interest rate and matures on December 30, 2026, unless extended by both parties. The company plans to use the proceeds for general working capital.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

18506U203

FAQ

Who are the top institutional investors holding CLEARONE INC (CLRO)?

Major stakeholders currently include Shay Capital LLC ($197.9K), T3 Companies, LLC ($106.8K), Albion Financial Group /ut ($51.5K). Based on the latest 13F filings, there are a total of 9 tracked investment funds and institutions maintaining positions in CLRO.

What is the overall institutional sentiment toward CLRO recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $34.1K, driven by 3 managers accumulating shares while 4 reduced their exposure.

Which institutions have been selling or reducing their CLRO positions?

In the latest period, 1 funds trimmed their holdings, and 3 managers completely exited their positions. The aggregate reported sell value was $158.8K.

Are there any notable investors adding CLRO to their portfolios?

Yes, buying activity remains notable. 1 institutions opened new positions in {ticker}, and 2 existing holders added to their shares. The total reported buy value for the quarter amounted to $352.3K.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,153

Total reported value

$2.1T

3246 13F institutions increased their position this quarter

View detail

AMZN

Amazon.com INC

Institutions Holding

5,960

Total reported value

$1.5T

3030 13F institutions increased their position this quarter

View detail

NVDA

Nvidia CORP

Institutions Holding

5,769

Total reported value

$3.0T

2744 13F institutions increased their position this quarter

View detail

Developer Access

Access CLRO's institutional ownership data programmatically:

REST API

curl https://alphasmo.com/api/v1/market/stock/CLRO

CLI

npx alphasmo stocks get CLRO

Full API & MCP documentation →